Beyond Air, Inc. Stock News

Abstracts for the American Association for Cancer Research (AACR) Annual Meeting were released publicly today at 4:30 PM ET Abstracts for the American Association for Cancer Research (AACR) Annual Mee

LungFit® PH premarket approval (PMA) submission under active review by U.S. FDA; approval and commercial launch anticipated in the first half of calendar year 2022 along with European CE Mark

LungFit ® PH premarket approval (PMA) submission under active review by U.S. FDA; approval and commercial launch anticipated in the first half of calendar year 2022 along with European CE Mark

Beyond Air, Inc.'s (XAIR) CEO Steve Lisi on Q3 2022 Results - Earnings Call Transcript

GARDEN CITY, N.Y., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for

Mr. David Dvorak, previously the President and CEO of Zimmer Biomet, brings a 25+ year proven track record of executive leadership, operating experience, and board memberships

Mr. David Dvorak, previously the President and CEO of Zimmer Biomet, brings a 25+ year proven track record of executive leadership, operating experience, and board memberships Dr. Gregory Berk joins with 30+ years of medical experience with oncology expertise in clinical trials, drug development, and regulatory strategy in both industry and academia GARDEN CITY, N.Y., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR ), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced the appointments of Mr. David Dvorak and Dr. Gregory Berk to Beyond Cancer''s Board of Directors. Following these appointments, the Beyond Cancer Board of Directors will be comprised of six members with no further additions planned.

ARAY, XAIR, and EMKR have been added to the Zacks Rank #5 (Strong Sell) List on January 27, 2022

Call scheduled for Thursday, February 10th at 4:30 pm Eastern Time Call scheduled for Thursday, February 10th at 4:30 pm Eastern Time

ARAY, XAIR, and EMKR have been added to the Zacks Rank #5 (Strong Sell) List on January 27, 2022

Call scheduled for Thursday, February 10th at 4:30 pm Eastern Time Call scheduled for Thursday, February 10th at 4:30 pm Eastern Time

TELA Bio (NASDAQ:TELA) and Beyond Air (NASDAQ:XAIR) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, analyst recommendations, institutional ownership and profitability. Profitability This table compares TELA Bio and Beyond Airs net margins, return on equity and []

Beyond Air CEO Steven Lisi recently bought the dip in XAIR stock, increasing his stake by ~4%. I see no attempt in Mr. Lisi's actions to artificially pump the stock to sell his stake at a higher price